Skip to main content
. Author manuscript; available in PMC: 2015 Jan 5.
Published in final edited form as: Transfusion. 2012 Feb 10;52(10):2209–2219. doi: 10.1111/j.1537-2995.2011.03550.x

Figure 5. Delayed CTLA4-Ig treatment is ineffective at preventing LR-PLT induced BMT rejection.

Figure 5

(A) Experimental model testing the ability of CTLA4-Ig to prevent platelet induced rejection of an MHC-matched BMT when administered at the time of BMT. Recipients received four LR-PLT transfusions, a week apart. After the fourth transfusion, recipients received a BALB.B BMT under reduced intensity conditions with or without a single 500 µg dose of CTLA4-Ig or human IgG1 i.p. two hours prior to transplantation. (B) Engraftment is represented as percent CD229.1+ cells in the peripheral blood; the horizontal lines denote the mean of each group. Rejection was measured as having a percent CD229.1+ cells engraftment two standard deviations above the mean of the positive control group known to reject, recipients treated with isotype control antibody human IgG1. Statistics were generated using column statistics and a one-way ANOVA with Dunnett’s post-test. The combined data from three independent experiments are shown.